These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 24848373)

  • 1. Lipoprotein(a) as a therapeutic target in cardiovascular disease.
    Koschinsky M; Boffa M
    Expert Opin Ther Targets; 2014 Jul; 18(7):747-57. PubMed ID: 24848373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein(a), cardiovascular disease, and contemporary management.
    Jacobson TA
    Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein(a): an important cardiovascular risk factor and a clinical conundrum.
    Koschinsky ML; Boffa MB
    Endocrinol Metab Clin North Am; 2014 Dec; 43(4):949-62. PubMed ID: 25432390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapeutic agents to lower lipoprotein (a) levels.
    Kolski B; Tsimikas S
    Curr Opin Lipidol; 2012 Dec; 23(6):560-8. PubMed ID: 23041907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein (a): gene genie.
    Durrington PN; Schofield JD; Siahmansur T; Soran H
    Curr Opin Lipidol; 2014 Aug; 25(4):289-96. PubMed ID: 24977982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?
    Hung MY; Tsimikas S
    Curr Opin Lipidol; 2014 Dec; 25(6):423-30. PubMed ID: 25340480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperlipoproteinemia(a): clinical significance and treatment options.
    Berthold HK; Gouni-Berthold I
    Atheroscler Suppl; 2013 Jan; 14(1):1-5. PubMed ID: 23357133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein(a)--An independent causal risk factor for cardiovascular disease and current therapeutic options.
    Kassner U; Schlabs T; Rosada A; Steinhagen-Thiessen E
    Atheroscler Suppl; 2015 May; 18():263-7. PubMed ID: 25936335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein(a): more interesting than ever after 50 years.
    Dubé JB; Boffa MB; Hegele RA; Koschinsky ML
    Curr Opin Lipidol; 2012 Apr; 23(2):133-40. PubMed ID: 22327610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.
    Boffa MB
    Curr Atheroscler Rep; 2016 Dec; 18(12):69. PubMed ID: 27761705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The Evolution of Views on Lipoprotein(a): From Biomarker to the Therapeutic Target].
    Safarova MS; Ezhov MV
    Kardiologiia; 2015; 55(4):71-82. PubMed ID: 26502507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies.
    Tsimikas S; Hall JL
    J Am Coll Cardiol; 2012 Aug; 60(8):716-21. PubMed ID: 22898069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current therapies for lowering lipoprotein (a).
    van Capelleveen JC; van der Valk FM; Stroes ES
    J Lipid Res; 2016 Sep; 57(9):1612-8. PubMed ID: 26637277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
    Leebmann J; Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Maerz W; Lehmacher W; Heibges A; Klingel R;
    Circulation; 2013 Dec; 128(24):2567-76. PubMed ID: 24056686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein(a)-clinical aspects and future challenges.
    Kurt B; Soufi M; Sattler A; Schaefer JR
    Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):26-32. PubMed ID: 25732622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When should we measure lipoprotein (a)?
    Kostner KM; März W; Kostner GM
    Eur Heart J; 2013 Nov; 34(42):3268-76. PubMed ID: 23735860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lipoprotein(a) as a cardiovascular risk factor].
    van Lennep JE; Mulder MT
    Ned Tijdschr Geneeskd; 2011; 155(42):A3582. PubMed ID: 22027461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated lipoprotein(a) levels: A crucial determinant of cardiovascular disease risk and target for emerging therapies.
    Afzal Z; Cao H; Chaudhary M; Chigurupati HD; Neppala S; Alruwaili W; Awad M; Sandesara D; Siddique M; Farman A; Zafrullah F; Gonuguntla K; Sattar Y
    Curr Probl Cardiol; 2024 Aug; 49(8):102586. PubMed ID: 38653440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein(a) Antisense Oligonucleotides: A New Treatment Option for Lowering Elevated Lipoprotein(a)?
    Schreml J; Gouni-Berthold I
    Curr Pharm Des; 2017; 23(10):1562-1570. PubMed ID: 28128058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein(a): cardiovascular risk and emerging therapies.
    Fujino M; Nicholls SJ
    Expert Rev Cardiovasc Ther; 2023 Apr; 21(4):259-268. PubMed ID: 37010028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.